The prognostic value and clinical utility of estrogen and progesterone receptors in endometrial carcinoma

Primary Care Update for Ob/Gyns

Volumn 7, Issue 2, 2000, Pages 55-59

  Gehrig, Paola A ^a   Van Le, Linda ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

CANCER SURVIVAL; DIAGNOSTIC VALUE; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY;

EID: 0034603324     PISSN: 1068607X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1068-607X(00)00021-4     Document Type: Article

References (18)

1. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer Stats 1998. CA Cancer J Clin. 49:1999;12-13.
2. Hoskins WJ, Perrez CA, Young RC. Principles and Practices of Gynecologic Oncology, 2nd Edition. Philadelphia (PA) Lippincott-Raven, 1997:860.
3. Kurman R.J., Kalminski P.R., Norris H.J. The behavior of endometrial hyperplasia a long term study of "untreated" hyperplasia in 170 patients . Cancer. 56:1985;403.
4. McDonnell DP. Selective estrogen receptor modulators (SERMS). Menopausal Medicine 1998;6(4):1-5.
5. Chambers J.T., Carcangiu M.L., Voynick I.M., Schwartz P.E. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Am J Clin Pathol. 94:1990;255-260.
6. Soper J.T., Segreti E.M., Novotny D.B., Mutch D., Creasman W.T., McCarty K.S. Estrogen and progesterone receptor content of endometrial carcinomas comparison of total tissue versus cancer component analysis . Gynecol Oncol. 36:1990;363-368.
7. Fukuda K., Mori M., Uchiyama M., Iwai K., Iwasaka T., Sugimori H. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol Oncol. 69:1998;220-225.
8. Pichon M.F., Broet P., Magdelenat H., Delarue J.C., Spratus F., et al. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer. 73:1996;1545-1551.
9. Creasman W.T. Prognostic significance of hormone receptors in endometrial cancer. Cancer. 71:1993;1467-1470.
10. Chambers J.T., MacLusky N., Eisenfield A., Kohorn E.I., Lawrence R., Schwartz P.E. Estrogen and progestin receptor levels as prognosticators for survival in endometrial cancer. Gynecol Oncol. 31:1988;65-77.
11. Ingram S.S., Rosenman J., Heath R., Morgan T.M., Moore D., Varia M. The predictive value of progesterone receptor levels in endometrial cancer. Int J Radiat Oncol Biol Phys. 17:1989;21-27.
12. Ehrlich C.E., Young P.C.M., Stehman F.B., Sutton G.P., Alford W.M. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol. 158:1988;796-807.
13. Kleine W., Maier T., Geyer H., Pfleiderer A. Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance. Gynecol Oncol. 38:1990;59-65.
14. Quinn M.A., Cauchi M., Fortune D. Endometrial carcinoma steroid receptors and response to medroxyprogesterone acetate . Gyn Oncol. 21:1985;314-319.
15. USP DI Oncology Drug Information, 2nd Edition. Rockville (MD): ACCC, 1998:361-79.
16. Fisher B., Constatino J.P., Redmond C.K., et al. Endometrial cancer in tamoxifen-treated breast cancer patients findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) . J Natl Cancer Inst. 86:1994;527-537.
17. ACOG Committee Opinion. The American College of Obstetricians and Gynecologists. 1996;169:231-33.
18. Bonte J., Ide P., Billiet G., Wynants P. Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma. Gynecol Oncol. 11:1981;140-161.